FDA: Oncology deep learning, AI imaging software receives clearance

A new broad oncology deep learning suite from the cloud-based medical imaging software solutions company Arterys Inc. was approved on Thursday, Feb. 15 for 501(k) clearance by the FDA, according to a report by Business Insider.  

The clearance is for Aterys new Oncology AI software aimed to advance medical imaging accuracy and consistency, according to the report. This is the fifth FDA clearance Arterys has received for its deep learning cloud-based software.  

Specifically, the deep learning oncology software will be able to help clinicians measure and track tumors or potential cancers in solely liver and lung magnetic resonance imaging (MRI) and computed tomography (CT) scans and apply radiological standards with ease.  

"The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer," said radiologist and Arterys co-founder Albert Hsiao, MD, PhD, in a prepared statement. "We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS; the Oncology Lung AI and Liver AI products are designed to maximize efficiency and accuracy of the radiologist read and will power next-generation radiology interpretation."